Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Operating Expenses (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Operating Expenses data on record, last reported at $44.1 million in Q2 2025.

  • For Q2 2025, Operating Expenses fell 10.68% year-over-year to $44.1 million; the TTM value through Dec 2025 reached $92.1 million, down 70.27%, while the annual FY2025 figure was $173.7 million, 7.46% down from the prior year.
  • Operating Expenses reached $44.1 million in Q2 2025 per TNGX's latest filing, down from $47.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $167.1 million in Q4 2024 and bottomed at $18.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $43.5 million, with a median of $36.9 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: surged 4811128.81% in 2021, then decreased 10.68% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $27.7 million in 2021, then surged by 33.49% to $37.0 million in 2022, then increased by 9.38% to $40.4 million in 2023, then surged by 313.06% to $167.1 million in 2024, then tumbled by 73.57% to $44.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $44.1 million in Q2 2025, $47.9 million in Q1 2025, and $167.1 million in Q4 2024.